

1 **A cell circuit approach to dissect fibroblast-macrophage interactions in the tumor**
2 **microenvironment**

3
4 Shimrit Mayer^{1*}, Tomer Milo^{2*}, Achinoam Isaacson¹, Coral Halperin¹, Shoval Miyara², Yaniv
5 Stein¹, Meirav Pevsner-Fischer¹, Eldad Tzahor², Uri Alon² and Ruth Scherz-Shouval^{1#}

6
7 ¹Department of Biomolecular Sciences, The Weizmann Institute of Science, Rehovot, Israel

8 ²Department of Molecular Cell Biology, The Weizmann Institute of Science, Rehovot, Israel

9
10 * These authors contributed equally to this manuscript

11 # Corresponding author: ruth.shouval@weizmann.ac.il

12
13
14 **Abstract**

15 The tumor microenvironment (TME) is composed of various nonmalignant cell types that interact
16 with each other and with cancer cells, impacting all aspects of cancer biology. The TME is
17 complex and heterogeneous, and thus simplifying systems and concepts are needed. Here we
18 provide a tractable experimental system and powerful mathematical circuit concepts to identify
19 the main molecular interactions that govern the composition of the TME. We focus on two major
20 components of the TME - cancer associated fibroblasts (CAFs) and tumor associated
21 macrophages (TAMs), define their interactions and verify our predictions in mouse and human
22 breast cancer. We measure the population dynamics starting from many initial conditions of co-
23 cultures of macrophages and organ-derived fibroblasts from mammary, lung, and fat, and explore
24 the effects of cancer-conditioned medium on the circuits. We define the circuits and their inferred
25 parameters from the data using a mathematical approach, and quantitatively compare the cell
26 circuits in each condition. We find that while the homeostatic steady-states are similar between
27 the organs, the cancer-conditioned medium profoundly changes the circuit. Fibroblasts in all
28 contexts depend on autocrine secretion of growth factors whereas macrophages are more
29 dependent on external cues, including paracrine growth factors secreted from fibroblasts and
30 cancer cells. Transcriptional profiling reveals the molecular underpinnings of the cell circuit
31 interactions and the primacy of the fibroblast autocrine loop. The same fibroblast growth factors
32 are shared by the co-cultures and mouse and human breast cancer. The cell circuit approach
33 thus provides a quantitative account of cell interactions in the cancer microenvironment.

34 **Introduction**

35 Tumors are complex ecosystems in which cancer cells interact with diverse non-malignant cells
36 of the tumor microenvironment (TME). It is through these interactions that tumors progress and
37 metastasize, and these interactions impact all aspects of cancer biology¹⁻³. Major components in
38 the tumor microenvironments (TME) of most carcinomas are fibroblasts and macrophages, known
39 as cancer associated fibroblasts (CAFs) and tumor associated macrophages (TAMs)^{4,5}. Defining
40 the inherent principles and molecular signals of CAF and TAM interactions is critical for our
41 understanding of the TME and for finding ways to improve cancer therapy.

42 Fibroblasts and macrophages are basic tissue components of every organ in the body, and key
43 regulators of organ homeostasis^{6,7}. In healthy tissues, fibroblasts produce the extracellular matrix
44 (ECM) that gives structure to the organ and limits the proliferation and differentiation of epithelial
45 cells^{8,9}. Macrophages serve as sentinels that detect stress signals and phagocytose invading
46 pathogens, apoptotic cells and ECM degradation products⁶. Upon injury or inflammation,
47 circulating monocytes infiltrate the organ and differentiate into macrophages. These bone-
48 marrow-derived macrophages (BMDMs)¹⁰ work together with the resident macrophages and
49 fibroblasts. The resident fibroblasts transition into *myofibroblasts* that produce copious ECM,
50 which is further remodeled by the BMDMs in a reciprocal process of wound healing. Both in
51 normal homeostasis and following injury, fibroblasts have additional roles beyond ECM
52 production, influencing epithelial stem cell behavior, promoting angiogenesis and coordinating
53 immune function through production of chemokines and cytokines^{11,12}.

54 In severely injured or chronically inflamed tissues, fibroblasts produce excessive ECM, and
55 macrophages remodel the ECM through production of ECM-modifying enzymes such as
56 metalloproteases^{8,13}. The excessive production and remodeling of ECM may result in fibrosis, in
57 which tissue is replaced with scar. Eventually, fibrosis can lead to cancer^{14,15}. Fibroblasts in
58 cancer are rewired to become protumorigenic CAFs that support tumor progression, invasion,
59 and metastasis by secreting cytokines, chemokines, extracellular matrix components and growth
60 factors^{11,12}. CAFs also promote the recruitment of monocytes from the bone-marrow and their
61 differentiation into TAMs, which then stimulate angiogenesis, enhance tumor cell migration and
62 invasion, and suppress antitumor immunity¹⁴.

63 Fibroblasts and macrophages are transcriptionally and phenotypically heterogeneous. One facet
64 of this heterogeneity is that different organs have different characteristic populations of resident
65 fibroblasts. Advances in single-cell RNA sequencing and imaging technologies defined multiple

66 subpopulations of fibroblasts in healthy, and even more so in diseased tissues ¹⁶. These
67 subpopulations have distinct functions related to ECM production, adhesion and immune
68 regulation ¹⁷⁻¹⁹. In many cases these subpopulations represent dynamic cell states induced by
69 changes in microenvironmental conditions ¹⁸. Infiltrating macrophages come from a shared
70 monocyte origin, and can switch between pro-inflammatory and anti-inflammatory states,
71 contributing to phenotypic plasticity of diseased tissues ^{20,21}.

72 Heterogeneous populations of fibroblasts and macrophages engage in complex cell-cell
73 interactions. To understand these interactions, simplifying concepts are essential. One such
74 concept is the cell circuit ²². Cell circuits describe the dynamics of cell numbers for several cell
75 types according to the growth factors they exchange and constraints imposed by their
76 environment. Recently, a prototype circuit model for fibroblast-macrophage interactions in tissue
77 homeostasis was defined using *ex-vivo* co-cultures of mouse embryonic fibroblasts (MEFs) with
78 BMDMs ^{22,23}. Fibroblasts, however, are heterogeneous and evolve to perform organ-specific tasks
79 ^{11,16}. In tumors, fibroblasts evolve and diverge into distinct subpopulations with distinct functions
80 such as immune-modulation, ECM production and antigen-presentation ^{12,18,24,25}. It remains
81 unknown what the cell circuits are in the cancer microenvironment, and how they differ from the
82 normal cell circuits in different organs.

83 Here we address these questions by developing a cell circuit approach that combines
84 experimental co-culture and mathematical modeling to infer circuit parameters, such as the
85 autocrine and paracrine interactions between multiple cell types, and compare between different
86 cell circuits. We apply this approach to co-cultures of BMDMs with fibroblasts from three different
87 organs - mammary, lung, and mesometrial fat - and explore the effects of cancer-conditioned
88 medium on the circuits. We find that the homeostatic steady states are similar between the
89 organs, but changes in growth conditions from normal to cancer-conditioned medium profoundly
90 alter the circuit interactions. In all contexts, fibroblasts support their own growth by an autocrine
91 loop of growth factors, whereas macrophages are more dependent on external growth factors
92 secreted by fibroblasts and cancer cells. RNA sequencing of the co-cultures supports the inferred
93 circuit interactions and their relative strengths, and highlights potential growth factors driving these
94 interactions. Comparative transcriptomic analysis of mouse and human breast cancer reveals that
95 the fibroblast autocrine loop is the strongest interaction in all circuits, and that the growth factors
96 that comprise it are shared by the circuits found in the *in-vitro*-simulated cancer microenvironment
97 and the microenvironment of mouse and human breast cancer. Together, our findings establish

98 principles of cell circuit design, and provide a quantitative approach to model cell interactions in
99 an organ- and disease-specific manner.

100 **Results**

101 **Experimental phase portraits show multiple steady-states for macrophage-fibroblast** 102 **circuits which are similar across organs, but perturbed in cancer-conditioned medium**

103 To define cell circuits in different organs and cancer contexts, we established a co-culture assay
104 for cell population dynamics. As a baseline, we used fibroblasts from the mammary fat pad and
105 later we compared them with fibroblasts from fat and lung to explore organ context. We then
106 compared growth in control medium to breast cancer-conditioned medium (CM), to explore tumor
107 context.

108 We co-cultured BMDMs with tissue-resident fibroblasts from the mammary fat pad of syngeneic
109 BALB/c mice using a previously described approach for mouse embryonic fibroblasts²². Cell
110 growth from different initial concentrations of fibroblasts and BMDMs was tracked by flow
111 cytometry after 3 or 7 days of co-culture (Figure S1A), and plotted in a *phase portrait*. The phase
112 portrait has two axes: the fibroblast (X-axis) and macrophage (Y-axis) cell counts. Arrows
113 (vectors) on the phase portrait indicate how cell counts change from day 3 to day 7 (Figure 1A).

114 Macrophages in mono-culture could not promote their own growth under these experimental
115 conditions (Figure 1B), but co-culture with fibroblasts supported macrophage growth, and
116 revealed dynamic interactions (Figure 1C).

117 The phase portrait shows several points of interest that characterize the dynamic system, called
118 fixed points, in which cell counts remain approximately constant^{22,26}. One fixed point is the ON
119 state (Figure 1C, green dot) with high numbers of fibroblasts and macrophages. In this state,
120 macrophages and fibroblasts continually turn over as indicated by EdU incorporation
121 measurements (Figure S1B-C; see Methods), but maintain their numbers in a dynamic steady
122 state. *In vivo*, this state may occur following injury, as fibroblasts and macrophages are recruited
123 to repair wounded tissue. If the injury is not resolved, fibroblasts and macrophages maintain high
124 numbers in a state of chronic inflammation and fibrosis^{10,23}.

125 When fibroblasts grow alone their growth dynamics depend on their initial numbers. Below a
126 critical threshold, which is an unstable fixed point (Figure 1C, white dot), fibroblast numbers
127 decline to zero. This represents the healthy state of a tissue, and it is the expected outcome of
128 successful resolution of acute injury or acute inflammation. Above this threshold, fibroblasts are

129 able to maintain themselves, and their numbers rise to a fixed point called the ON-OFF state
130 (fibroblasts are ON, macrophages are OFF, Figure 1C, half-yellow dot). Fibroblasts at this fixed
131 point continually turn over in a dynamic steady-state, as indicated by EdU incorporation (Figure
132 S1B). In physiological terms, a state in which fibroblasts maintain high numbers in the absence
133 of macrophages is referred to as 'cold fibrosis'²³, and it is distinct from the ON state, which has
134 macrophages instead.

135 When macrophages are added to the ON-OFF state, the macrophage number increases and
136 converges to the ON state (Figure 1C, green dot). Thus the ON-OFF fixed point is semi-stable,
137 and the cold fibrosis state leads to 'hot' fibrosis.

138 An additional fixed point is at zero cells, denoted as the OFF state (Figure 1C, red dot). The phase
139 portrait indicates that this state is reached when initial fibroblast and macrophage concentrations
140 are low. Physiologically, as mentioned above, this can be viewed as a healing state, in which
141 myofibroblasts and inflammatory macrophages are no longer present.



142 We tested the robustness of the phase portrait assay in several ways (Figure S1D-G). Biological
143 replicates of the experiment gave rise to similar phase portraits (Figure S1D). Phase portraits
144 derived from cell counts at days 7, 14, and 21 showed a qualitatively similar convergence towards
145 the "ON" and "ON-OFF" states found for cell counts derived from days 3 and 7 (Figure S1E),
146 suggesting approximate temporal invariance. We repeated the analysis using a different mouse
147 strain, C57BL/6, and obtained a similar phase portrait (Figure S1F). To accurately measure
148 growth dynamics at very low initial cell concentrations (several cells per well) we scaled the
149 experiment up from 96-well plates to 6-well plates, which have a 30-fold larger area. We
150 accordingly multiplied cell numbers measured in 96-wells by a factor of 30. We tested the validity
151 of this approach by measuring overlapping regions of similar effective concentrations in 96 and 6
152 wells, and found qualitative agreement (Figure S1G, red vs. gray arrows).

153 We further asked whether addition of macrophages to an on-going culture of fibroblasts -
154 simulating the infiltration of BMDMs into a tissue populated by resident fibroblasts - would yield
155 similar interaction dynamics compared to those observed by simultaneous plating of both cell
156 types. We observed similar convergence towards the ON state when macrophages were either
157 added to the cultures 3 days after the initial plating of fibroblasts, or simultaneously plated with
158 fibroblasts, suggesting that the interaction dynamics are independent of this variable (Figure S1G,
159 pink arrows). This finding further supports the conclusion that the ON-OFF state is semi-stable.

160 Next, we used this assay to test the effect of organ context on the phase portrait. We sought to
161 understand whether resident fibroblasts from different organs have similar or different interaction
162 circuits with infiltrating macrophages. For this purpose, we isolated fibroblasts from two additional
163 organs, lung and mesometrial fat. We determined the phase portrait for these fibroblasts grown
164 with BMDMs (Figure 1D-E), and compared them to the phase portrait from mammary fibroblasts.
165 The phase portraits from all three organs showed similar fixed point structures and robustness
166 criteria (Figure 1C-E, Figure S1D-G, and Figure S2A-F). The three portraits had an OFF state
167 (red dots), an unstable fixed point located on the x axis (white dots), an ON-OFF state (half-yellow
168 dots) in which fibroblasts maintain their own numbers, and an ON state (green dots) in which
169 fibroblasts and macrophages support each other in a dynamic steady state.
170 The position of the fixed points was similar in all three organ contexts. The ON state was
171 composed of $\sim 10^5$ fibroblasts and $\sim 10^5$ macrophages (Figure 1C-E), and the ON-OFF state had
172 $\sim 10^5$ fibroblasts in all three organs. Additionally, the fixed points showed similar cell sizes
173 measured by microscopy (Figure S2G-H). These findings suggest that the homeostatic steady-
174 state concentrations of fibroblasts and macrophages are similar across organ contexts.
175 We next asked how the circuits might be affected by pathological conditions. In particular, cancer
176 cells rewire their microenvironment, with effects on fibroblasts and macrophages^{11,12,27}. To test
177 this, we used cancer conditioned medium (CM) in the co-culture system and measured changes
178 in the phase portraits of fibroblasts and macrophages, using the mammary fat pad as a baseline
179 system.
180 We grew 4T1 triple-negative breast cancer cells syngeneic to the fibroblasts and BMDMs, and
181 collected their CM at 48 hours. We added the cancer CM to co-cultures of mammary fibroblasts
182 and BMDMs, and obtained the experimental phase portrait (Figure 1F-G; red arrows).
183 In the presence of cancer CM (Figure 1F-G) the phase portrait was very different from control
184 medium (Figure 1C). Macrophages in cancer CM were able to grow in the absence of fibroblasts
185 (Figure 1F), in contrast to control media, in which their growth was found dependent on fibroblasts
186 (Figure 1B). This may relate to the composition of 4T1-conditioned medium which contains factors
187 that regulate macrophage proliferation²⁸. As a result, the OFF state, which was stable in the
188 control medium, becomes semi-stable in the presence of cancer CM, and is lost when
189 macrophages are added. The ON and ON-OFF states are still observed with cancer CM (Figure
190 1G).

191 The phase portraits highlight the dynamic nature of the fibroblast-macrophage interaction, the
 192 codependence of macrophages and fibroblasts, and the strong effect of cancer condition media
 193 on these dynamics.

A



194

195 **Figure 1: Phase portraits of fibroblasts and macrophages are similar in different organ**
 196 **contexts, but perturbed by cancer-conditioned medium. A.** Illustration of the experimental
 197 procedure. Bone-marrow derived macrophages and fibroblasts from the indicated organs were
 198 isolated from mice, co-cultured at different ratios for 3 or 7 days in control or cancer-conditioned
 199 medium (CM), and then counted by flow cytometry. **B-G.** Experimental phase portraits of
 200 macrophage-fibroblast dynamics *in-vitro*. Arrow tails represent cell counts at day 3 of co-culture,
 201 and arrowheads represent cell counts at day 7 (starting from the same initial cell concentration).
 202 **B.** Mono-cultured macrophages are presented. **C-E.** Mammary, lung, and fat fibroblasts co-

203 cultured with macrophages are presented above the horizontal dashed lines. Mono-cultured
204 fibroblasts from these organs are presented below the dashed lines of these plots. Fixed points
205 are denoted as follows: The “ON” state: green dot; “OFF” state: red dot; unstable point: white
206 dot; “ON-OFF” state: half-yellow dot. Data are combined from at least three independent
207 experiments, with the following total number of biological replicates: macrophages only: n=5;
208 mammary: n=24; lung: n=16; fat: n=10. **F.** Experimental phase portrait of macrophages grown in
209 mono-culture in the presence of conditioned media (CM) derived from 4T1 breast cancer cells
210 (red arrows), overlaid on the control phase portrait presented in Figure 1B (gray arrows). Data
211 are combined from 3 independent experiments (performed in parallel to control media cultures);
212 n=10 biological replicates. **G.** Experimental phase portrait of macrophage-mammary fibroblast
213 dynamics following *in-vitro* co-culture with 4T1 CM (red arrows), overlaid on the control
214 mammary phase portrait presented in Figure 1C (gray arrows). Mammary fibroblasts co-cultured
215 with macrophages are presented above the horizontal dashed line; mono-cultured fibroblasts are
216 presented below the dashed lines of the plot. Data is combined from 5 independent experiments
217 (performed in parallel to control media co-cultures); n=12 biological replicates for the cancer CM.

218 **Mathematical modeling infers distinct cell circuits for different contexts**

219 The phase portrait provides a quantitative view of the dynamics that allows inferring the underlying
220 circuits. We therefore asked whether the phase portraits (Figure 1C-E) emerge from similar or
221 distinct underlying circuits of cell-cell interactions. To infer the cell circuits that give rise to the
222 phase portraits, we developed a mathematical model of interacting fibroblasts (F) and
223 macrophages (M) (Figure 2A-B), which simplifies a more complex model of biochemical reactions
224 ^{22,26}, in order to provide a minimal number of effective interaction parameters. This simplification
225 makes it possible to infer the parameters from the data without overfitting concerns. The model
226 has 4 parameters per cell type (Figure 2B; equations provided in Methods). Fibroblasts are
227 removed at rate r_F . Their proliferation is induced by paracrine interactions from macrophages at
228 rate p_{MF} , and by an autocrine loop at rate p_{FF} . Fibroblast numbers can not exceed a carrying
229 capacity K_F , which is limited by environmental factors such as nutrients and space availability
230 ^{22,29}. Four analogous parameters define macrophage dynamics: removal r_M , paracrine and
231 autocrine interactions p_{FM} and p_{MM} , and a carrying capacity K_M .

232 We estimated the values of the parameters by fitting calculated to observed cell numbers at day
233 7 given their number at day 3, for each organ context. We tested the relevance of each parameter
234 using standard information criteria by refitting the model when the parameter is set to zero (Figure
235 S3A-H). The parameters discussed next are all justified by the information criteria. The model
236 showed good fits to the experimental dynamics (Figure S3I-P) explaining 84%-93% of the
237 variance in the data.

238 The models with their best-fit parameters give rise to theoretical phase portraits (Figure 2C-F,
239 S3A-H; see Methods). These phase portraits are similar to the experimental ones, and help to fill

240 out regions that were difficult to reach experimentally (e.g., low cell numbers). The phase portraits
241 show the ON, ON-OFF, and OFF fixed points (Table 1, Figure 2C-F), as well as the unstable fixed
242 points. The inferred portraits also delineate the basins of attraction for the ON and OFF states
243 (shaded in different colors; Figure 2C-F). The border between these basins is called a separatrix.

244 Despite the similarity of the phase portraits in the three organ contexts, their inferred circuits were
245 different (Figure 2G-R). Mechanistically, this suggests that the ON state is achieved differently in
246 the mammary circuit than in the fat and lung circuits.

247 In all cases, fibroblasts support their own growth by means of an autocrine loop (Figure S4E-G).
248 The ON state in the mammary circuit is achieved via a combination of the autocrine loop and a
249 weaker paracrine interaction with the macrophages (Figure 2O). In the lung and fat, in contrast,
250 fibroblasts grow by means of their autocrine loop without inferred paracrine support from
251 macrophages (Figure 2P-Q).

252 In all organs, the macrophages are dependent on fibroblasts (Figure S4I-K). In the mammary
253 circuit, the macrophages solely depend on paracrine signaling from fibroblasts, which pull them
254 along to the ON state, with no inferred autocrine loop ($p_{MM} = 0$). In contrast, in the lung and fat
255 circuits, the presence of fibroblasts induces a weak inferred macrophage autocrine loop (Figure
256 2K-L). The enhanced proliferation rate of the macrophages is balanced by an increased removal
257 rate (r_M) in the lung and fat (Figure 2N). Lung fibroblasts also have a weaker paracrine effect on
258 macrophages p_{FM} , compared to mammary and fat fibroblasts (Figure 2K).

259 In all cases, cell growth is limited by a carrying capacity, which is similar for the three organs
260 (Figure 2I,M). The inferred macrophage carrying capacity is 10-fold greater than the fibroblast
261 carrying capacity, consistent with other findings²⁹ (Figure 2SG-H).

262 The different circuits produce differences in the phase portraits. In the mammary circuit, the model
263 indicates a second unstable point located at low (but non-zero) numbers of fibroblasts and
264 macrophages (Figure 2C, white dot b). From this point cells can flow to either the ON state or the
265 OFF state. Lung and fat are missing this unstable fixed point. As a result, there is a new basin of
266 attraction in the lung and fat phase portraits, which is missing in the mammary fat pad (Figure 2C-
267 E, S4A-C). This basin of attraction is larger in the lung (orange region in Figure 2D).

268 Despite their differences, all these circuits are able to generate similar concentrations of cells at
269 the fixed points to within a factor of two between organs (Table 1), as observed. We conclude that
270 similar ON-states are achieved by different circuits in the three organs with lung and fat being

271 more similar to each other than to the mammary circuit. However, all circuits have a prominent
272 fibroblast autocrine loop, whereas macrophages depend on fibroblasts.

273 The theoretical phase portrait in cancer CM differs strongly from control medium. It shows a new
274 stable OFF-ON state of macrophages (Fibroblasts are OFF, macrophages are ON; Figure 2F,
275 orange dot), a shift of unstable fixed point b to higher macrophage concentrations, and a change
276 in the OFF state from stable in the control medium to semistable in cancer CM. Although
277 fibroblasts below a critical concentration still flow to the OFF state, addition of macrophages
278 causes the cells to flow to the new OFF-ON state with macrophages alone (Figure 2F, Figure
279 S4D; orange dot). Such a macrophage-only state, in which macrophages turn over and support
280 their own growth, may resemble aspects of macrophage activation syndrome and
281 autoinflammation^{30–32}.


282 This difference can be interpreted in light of the concepts of hot and cold fibrosis²³. In the cancer
283 CM circuit, healing (i.e. the OFF state) is a less likely scenario, and states of hot fibrosis (ON) or
284 autoinflammation (OFF-ON) are more likely to occur.

285 The new OFF-ON fixed point in which macrophages lose their dependence on fibroblasts is
286 explained by the inferred circuit in cancer CM (Figure 2R, Figure S4L). The removal rate of
287 macrophages is zero according to information criteria (Figure 3SH), signifying enhanced survival
288 in the conditioned medium (Figure 2N). Cancer CM changes all macrophage parameters to allow
289 their enhanced growth (Figure 2K-N).

290 The cancer CM also weakens the dependency of fibroblasts on macrophages, since the inferred
291 macrophage paracrine effect on fibroblasts is zero (Figure 2H). Fibroblast growth rate is therefore
292 self-sustaining regardless of their seeding ratio with the macrophages (Figure S4H). Their effect
293 on macrophages is reduced but non-zero, because the measured macrophage growth rate
294 increases with fibroblast number in CM (Figure 2R, Figure S4L).

295 These analyses suggest that cancer-conditioned medium has a strong effect on the phase portrait
296 and the inferred circuit. The two cell types become less dependent on each other. This has a
297 profound effect on macrophage growth, since their dependence on fibroblasts in normal growth
298 conditions is high. The effect on fibroblast growth is less profound, since they mainly depend on
299 their autocrine loop in control conditions, rather than on the presence of macrophages. Macrophages
300 are thus more dependent on external growth conditions - be it reciprocal signaling with fibroblasts
301 or factors secreted to the medium by cancer cells, whereas fibroblasts are more self-sufficient
302 and can support their own growth.

303



304
305

306 **Figure 2: Mathematical modeling infers distinct cell circuits for different biological**
307 **contexts. A-B.** Theoretical cell circuits with the model parameters: p_{FF} - fibroblast autocrine loop;
308 K_F - fibroblast carrying capacity; r_F - fibroblast removal; and p_{MF} - paracrine effect of macrophages
309 on fibroblasts. Analogous parameters for the macrophages are: removal r_M ; paracrine and
310 autocrine interactions p_{FM} and p_{MM} , respectively; and carrying capacity K_M . **C-F.** Theoretical
311 phase portraits showing dynamic interactions of macrophages with mammary, lung, fat
312 fibroblasts, and mammary fibroblasts with cancer CM (as indicated). Basins of attraction are
313 indicated by color: in the red area cells flow to the “OFF” state (red dot), or to the “OFF-ON” in
314 presence of cancer CM; in the green area flow is to the “ON” state (green dot); and in the orange
315 area cells flow to the “ON-OFF” state (half-yellow dot). **G.** Macrophages - mammary fibroblasts
316 **D.** Macrophages - lung fibroblasts. **E.** Macrophages - fat fibroblasts. **F.** Macrophages - mammary
317 fibroblasts with cancer CM (compared to the control mammary circuit parameters presented in
318 Figure 2G-N). **G-N.** Calculated values for the cell circuit model parameters of mammary, lung, fat,
319 and cancer CM. The distribution of each parameter is presented by its median (circle),
320 interquartile range (thick line), and 95% confidence interval (CI; thin line). Parameters at zero
321 were those removed by model selection according to information criteria. P-value was calculated
322 by bootstrapping, * $p < 0.05$, *** $p < 0.0005$. **O-R.** Theoretical cell circuits with the mean value of
323 each parameter for mammary, lung, fat, and cancer CM compared to the control mammary circuit
324 parameters presented in Figure 2O (left panel).

325 **Transcriptomic analysis reveals molecular factors underlying the circuits**

326 Our mathematical modeling approach suggests that cancer CM strongly affects the cell circuit,
327 and that the circuits underlying lung and fat fibroblast-macrophage interactions are more similar
328 to each other than to the mammary fat pad. In order to understand the differences in fibroblasts
329 between organs and the effects of cancer CM, we performed RNA-sequencing of fibroblasts and
330 macrophages after co-culture at concentrations near the ON, ON-OFF, and OFF-ON states.
331 Under normal growth conditions (control medium), co-culture with fibroblasts strongly affected the
332 macrophage transcriptome, as indicated by clustering analysis (Figure 3A, first split). The genes
333 affected by co-culture were similar between macrophages co-cultured with lung and fat fibroblasts
334 and differed from those induced by co-culture with mammary fibroblasts, as indicated by
335 clustering analysis (Figure 3A, second split).

336 Fibroblasts were not affected as strongly by co-culture with BMDMs. Their transcriptional
337 differences correlated with organ origin, with fat and lung fibroblasts being more similar to each
338 other than to mammary fibroblasts (Figure 3B). This supports the prediction that lung and fat
339 circuits are indeed similar to each other and different from the mammary circuit, as well as the
340 prediction that macrophages are affected by fibroblasts more than fibroblasts by macrophages.

341 To characterize these expression changes we performed pathway analysis using Metascape³³
342 (Supplementary Table 1). In macrophages, antigen processing and presentation (*H2-Aa*, *H2-Ab1*,
343 *Cd74*) and the response to viruses (*Cxcl10*, *Mx1*, *Irf7*) were shut down upon co-culture with

344 fibroblasts from all three organs (Figure 3A,E; Cluster 1). Co-culture with lung or fat fibroblasts
345 led to upregulation of genes involved in inflammation and chemotaxis (*Ccr5*, *Bmp2*, *Cxcl1*, *Cxcl2*;
346 Figure 3A,E; Cluster 2). The same pathways were also upregulated following co-culture with
347 mammary fibroblasts, but the genes were different (*Ccr1*, *Rarres2*, *Ccl12*; Figure 3A,E; Cluster
348 3). Genes involved in ECM organization were upregulated in macrophages co-cultured with
349 fibroblasts from all three organs (*Bgn*, *Serpinh1*, *Col3a1*, *, *Timp1*; Figure 3A,E; Cluster 4).*





350 Co-culture of macrophages with fibroblasts from all organs led to the upregulation of genes
351 involved in cell growth (*Zfhx3*, *Slit3*, *Socs3*) and in positive regulation of cell death (*ApoE*, *Rhob*,
352 *Bnip3*; Figure 3A,E; Cluster 4). This is consistent with the phase portrait in which the ON state is
353 characterized by continuous turn-over of macrophages and fibroblasts, as supported by EdU
354 measurements (Figure S1B-C).

355 To dissect organ- specific differences in fibroblasts , we performed pairwise comparisons of gene
356 expression changes between fibroblasts grown alone or with macrophages (Figure S5B,
357 Supplementary Table 2). 340 genes were differentially expressed in the mammary fat pad, 220 in
358 the lung, and 82 in the fat. In the mammary fat pad, but not in lung and fat, co-culture with
359 macrophages led to upregulation of genes involved in myeloid leukocyte activation (*Lat2*, *Trem2*,
360 *Fcgr4*) and immune effector processes (*Serping1*, *C1qa*, *Fas*; Figure 3F, Supplementary Table
361 2). In all organs, co-culture with macrophages induced genes involved in ECM organization
362 (*Lama2*, *Tnc*, *Loxl4*), inflammatory responses (*Adam8*, *C3*, *Cxcl10*, *Ccl12*, *Ccl6*), and chemotaxis
363 (*Il16*, *Ccl12*, *Ccl2*, *Ccl20*, *Ccl7*; Figure 3F, Supplementary Table 2).

364 ECM organization pathways were induced in the RNA sequencing data in both cell types. To
365 directly assess ECM deposition activity, we measured fibrillar collagen levels in different regions
366 of the phase portrait (Figure 3G-J, see Methods). As expected, macrophages alone did not
367 deposit collagen, while fibroblasts from all three organs did (Figure 3G). However, co-culture with
368 macrophages resulted in a 2-3 fold increase in collagen deposition by fibroblasts. Maximal
369 collagen deposition was measured near the ON state, suggesting that this state is not only the
370 joint steady-state of the two cell types, but also the state of highest ECM production (Figure 3H-
371 J). Taken together, the circuit analysis, transcriptional data, and ECM measurements support the
372 notion that the ON state represents a state of chronic inflammation and hot fibrosis.

373 Cancer CM strongly affected gene expression in each of the cell types, and this effect was
374 stronger than the effect of the co-culture (Figure 3C-D). Cancer CM in the ON state induced
375 inflammation, chemotaxis, and ECM organization pathways compared to the control medium

376 (Figure S5C-D, Supplementary Tables 3-4). This supports the prediction of the cell circuit where
377 the cancer CM has strong effects on both cell types and weakens the dependency between them.
378 In summary, the transcriptomic analysis supports organ similarities (lung and fat) and differences
379 (lung and fat vs. mammary), as well as the strong influence of cancer CM on macrophages and
380 fibroblasts, highlighting the potential use of our cell-circuit approach to better understand cell-cell
381 interactions.



383 **Figure 3: RNA sequencing supports predicted changes in macrophage and fibroblast cell**
384 **circuits in different organs, and in cancer-conditioned medium. A-D.** Heatmaps showing
385 hierarchical clustering of differentially expressed genes (DEGs; basemean > 5; |LogFoldChange|
386 > 1; FDR < 0.1). **A.** An additive effect model was used to compare DEGs between macrophages
387 mono-cultured (BMDMs day0), or co-cultured with fibroblasts from different organs.
388 Macrophages: n=4 mice. **B.** An interaction model (tissue and culture) was used to compare DEGs
389 between fibroblasts from different organs mono-cultured (only) or co-cultured with macrophages.
390 Mammary: n=5; lung: n=3; fat: n=2-3 mice **C.** An interaction model (medium and culture) was
391 used to compare DEGs between macrophages mono-cultured, or co-cultured with mammary
392 fibroblasts in DMEM vs cancer CM. The mono-cultured macrophages in DMEM were collected at
393 day 0 (since they cannot maintain themselves in DMEM for 7 days), and at day 7 in cancer CM.
394 The co-cultured macrophages were collected after 7 days of co-culture with mammary fibroblasts,
395 in either DMEM or cancer CM. Macrophages in DMEM: n=3, macrophages in cancer CM: n=4
396 mice. **D.** An interaction model (medium and culture) was used to compare DEGs between
397 fibroblasts mono-cultured (only), or co-cultured, with macrophages in cancer CM vs. DMEM.
398 Fibroblasts in DMEM n=3, Fibroblasts in cancer CM: n=2-4 mice. **E.** Pathway analysis of the
399 macrophage clusters from (A) was conducted using Metascape³³. Selected significant pathways
400 are shown, see full list in Supplementary Table 1. **F.** Pathway analysis was performed on the
401 differentially upregulated genes from the pairwise comparison between fibroblasts co-cultured vs
402 mono-cultured ($P < 0.05$; FDR < 0.05; Figure S5B). Selected significant pathways are shown, see
403 full list in Supplementary Table 2. **G-J.** Quantification of the amount of fibrillar collagen deposited
404 as measured by Sirius Red staining after 7 days of co-culture of macrophages and fibroblasts.
405 Macrophages only: n=4; mammary: n=3; lung: n=5; fat: n=4 biological replicates. Data are
406 combined from at least three independent experiments. Data are presented as mean.

407 **Fibroblasts depend on autocrine secretion of growth factors whereas macrophages** 408 **depend on paracrine cues**

409 The present approach identifies cell circuits and is supported by transcriptomic data. We next
410 sought to use transcriptomic data to identify the growth factors at play in the circuits, and the
411 relative strength of these growth factor interactions. For this purpose we employed the ICELLNET
412³⁴ ligand-receptor analysis framework. We focused on growth factor interactions since these are
413 the interactions simulated in the cell circuit, and scored growth factor exchange based on the
414 expression of ligands and receptors (Figure 4A-B, see Methods).

415 In both control and cancer CM, the interaction with the highest score was the autocrine loop of
416 the fibroblasts (p_{FF}), in which fibroblasts secrete growth factors and also express the receptor for
417 these factors. The autocrine loop was followed in magnitude by the paracrine interaction of the
418 fibroblasts on the macrophages (p_{FM}), then the paracrine interaction of the macrophages on
419 fibroblasts (p_{MF}), and finally the autocrine loop of the macrophages (p_{MM}). This order of strength,
420 $p_{FF} > p_{FM} > p_{MF} > p_{MM}$ (Figure 4A-B), is precisely the order predicted by the model for the
421 mammary circuit (Figure 2O,R).

422 The specific growth factors identified in the fibroblast autocrine loop depend on the organ-context
423 (Figure S6A-B, Supplementary Table 5). The prominent growth factors in the mammary fibroblast
424 autocrine loop are HGF and VEGFA, whereas fat and lung are more similar to each other and
425 include BDNF and MDK. These growth factors are known to be involved in inflammation and
426 wound healing ³⁵⁻³⁸. Cancer CM affects the fibroblast autocrine growth factor interactions,
427 independently of the presence of macrophages (S6C, Supplementary Table 5).

428 We conclude that the fibroblast autocrine loop is the highest scoring interaction in all contexts, in
429 accordance with the circuit predictions.

430 **CAFs in human and mouse tumors show similar circuits with shared growth factors to** 431 **those found in the co-culture system**

432 To test the physiological relevance of the circuit approach beyond *in-vitro* co-cultures, we
433 analyzed cancer associated fibroblasts (CAFs) and tumor associated macrophages (TAMs) from
434 mouse and human breast cancer.

435 First, we analyzed RNA-seq data of TAMs and CAFs from a 4T1 mouse model (see Methods),
436 and used ICELLNET ³⁴ to score growth factor interactions. The CAF autocrine loop had the
437 highest interaction score, followed by the paracrine interaction of CAFs on the TAMs, then the
438 paracrine interaction of the TAMs on CAFs, and finally the autocrine loop of the TAMs, supporting
439 the co-culture results (Figure 4C).

440 CAFs are heterogeneous and could potentially exhibit heterogeneous growth-factor interactions.
441 To test this, we mapped the differentially upregulated growth factor interactions in each of the
442 three main CAF subtypes - myofibroblastic (PDPN⁺LYC6⁻ pCAFs), immune regulatory
443 (PDPN⁺LYC6⁺ pCAFs), and antigen presenting (PDPN⁻ sCAFs) that we have previously identified,
444 and compared them to normal mammary fibroblasts ^{12,18}. We found that the autocrine interactions
445 upregulated in cancer are different between different CAF subtypes, suggesting that each CAF
446 subtype upregulates a distinct set of biological responses in cancer (Figure S6D, Supplementary
447 Table 5).

448 Next, we tested our model on human CAF and myeloid cell scRNA-seq data derived from breast
449 cancer patients ³⁹ using ICELLNET (Figure S6E-H, see Methods). Here too, the CAF autocrine
450 loop had the highest growth factor interaction score, followed by the paracrine interactions and
451 myeloid autocrine loop in the same order as above (Figure 4D). Furthermore, analysis of the three
452 major CAF subpopulations: myofibroblastic (MMP11), immune regulatory (C3) and antigen

453 presenting (HLA-DRA, CD74; Figure S6F,H), revealed distinct autocrine growth factors,
454 supporting our findings from the 4T1 mouse model and indicating that distinct CAF subtypes
455 engage in distinct biological autocrine interactions (Figure 4E-F, Supplementary Table 5).

456 Notably, the human CAF autocrine loops shared growth factors with the mouse and the co-culture
457 autocrine loops, indicating the robustness of the present findings. The shared autocrine growth
458 factors include *FGF7*, *TIMP1*, *CXCL12*, *TGFb1* and *VEGFA* (Figure 4G, Supplementary Table 5).
459 *TGFB1* and *CXCL12* have been shown to be essential for the transition of fibroblasts to CAFs in
460 breast cancer ⁴⁰. The CAF autocrine growth factors mentioned above are also known to enhance
461 the protumorigenic macrophage subsets ¹, and are able to promote cancer invasion and
462 proliferation ⁴¹. Moreover, *FGF7*, *VEGFA*, and *TIMP1* promote cancer migration, angiogenesis,
463 and remodeling of the extracellular matrix, and are known to be upregulated in breast cancer ^{42–}
464 ⁴⁴. Thus, these factors not only promote fibroblast proliferation but also rewire TAMs towards a
465 protumorigenic phenotype that promote cancer progression ^{45,46}. Furthermore, we found these
466 fibroblast autocrine factors in patients with different subtypes of breast cancer (ER⁺, HER2⁺, and
467 triple-negative). However, we did find additional unique fibroblast growth factors in patients with
468 different breast cancer subtypes. For example, *IL6* was only detected in triple-negative and
469 HER2⁺ breast cancer patients, but not in ER⁺ patients, while *FGF1*, *PGF* and *VEGFC* were only
470 detected in triple-negative breast cancer patients (Supplementary Table 5).

471 Finally, we analyzed the secreted paracrine growth factors expressed by the cancer cells and
472 CAFs and affecting TAMs in human and mouse tumors. Analysis of RNA-seq data of 4T1 cells
473 from murine tumors ⁴⁷ and human breast cancer ³⁹ revealed that cancer cells secrete factors for
474 macrophages including *CSF2* and *CSF3* in mice, and *AREG* in patients. This provides a rationale
475 for the OFF-ON state with macrophages alone in cancer CM (Figure 4H). The CAFs and cancer
476 cells from both mouse and humans shared ligands that were also observed in the CAF autocrine
477 loop, including *FGF7*, *TIMP1*, *CXCL12*, and *VEGFA* (Figure 4H-I, Supplementary Table 5). The
478 autocrine loops for these CAFs have higher scores than the paracrine interactions from cancer
479 cells (Figure S6I-J).

480

482 **Figure 4: Circuits and growth factors are shared between the co-cultures and the cancer**
483 **microenvironment of breast cancer from mice and human patients. A-D.** Growth factor
484 ligand-receptor scores for fibroblasts-macrophages based on RNA sequencing data. **A.** *In-vitro*
485 model of mammary fibroblasts-macrophages in the ON state with DMEM. **B.** *In-vitro* model of
486 mammary fibroblasts-macrophages in the ON state with cancer CM. **C.** *In-vivo* model of CAFs-
487 TAMs from 4T1 tumor-bearing mice. **D.** CAFs-TAMs from scRNA of human breast cancer. **E.** The
488 top 20 scoring growth factor ligand-receptor interactions of P_{FF} for mouse CAF populations. **F.**
489 The top 20 scoring growth factor ligand-receptor interactions of P_{FF} for human breast CAF
490 subpopulations. **G.** Venn diagram showing the shared growth factor ligands between fibroblasts
491 grown *in-vitro* in cancer CM (*in-vitro* CAFs), CAF from the 4T1 model in mice (*in-vivo* mouse
492 CAFs), and CAFs from human patients (*in-vivo* human CAFs). The gene scores were above 10,
493 and the *in-vitro* and *in-vivo* CAF scores were at least 2-fold higher than normal fibroblasts. **H-I.**
494 The top 20 scoring growth factor interactions of CAF and cancer ligands with TAM receptors, in
495 mouse and human, respectively.

496 **Discussion**

497 We present a cell circuit approach to understand the interactions between fibroblasts and
498 macrophages in the tumor microenvironment. We defined the cell circuits using phase-portraits
499 derived from the dynamics of *in-vitro* co-cultures. The experimental phase portraits display the
500 dynamics for many initial conditions at once, and we developed methods to infer the underlying
501 circuits and parameters. This allowed us to compare cell circuits from different organs and to
502 study the effect of cancer-conditioned medium on the circuit. Fibroblasts from lung, fat, and
503 mammary fat pad interact with co-cultured BMDMs to produce quantitatively similar fixed-point
504 structures: an ON state with fibroblasts and macrophages in continual turnover, an ON-OFF state
505 with fibroblasts only, and an OFF state with neither cell type. Cancer-conditioned medium
506 profoundly changes the circuit parameters and the phase portrait, creating a new fixed point of
507 macrophages without fibroblasts. In all contexts fibroblasts support themselves by an autocrine
508 loop, whereas macrophages are dependent on fibroblasts or external cues supplied by the cancer
509 cells. Transcriptomic analysis supports the circuit analysis and shows that circuits and growth
510 factors are shared between the co-cultures and the cancer microenvironment of breast cancer
511 from mice and human patients.

512 The present co-culture and modeling approach is minimal, and many physiological components
513 are missing, including spatial structure and other cell types. Nevertheless, we find that concepts
514 derived from the *in-vitro* system, such as the importance of the fibroblast autocrine loop, carry
515 over to the *in-vivo* context in both mouse and human breast cancer. Moreover, some of the main
516 growth factors are shared between the *in-vitro* and *in-vivo models*. This indicates that the phase
517 portrait approach may be useful to study the tumor microenvironment.

518 The phase portrait indicates that the fibroblasts and macrophages coexist at high concentrations
519 in an ON state with continual turnover and ECM production, as verified by EdU incorporation and
520 collagen staining assays. This ON state is supported by an autocrine loop where fibroblasts
521 secrete their own growth factors, and also by paracrine growth factor exchange between the cell
522 types. The circuit analysis indicated that the fibroblast autocrine loop is the strongest of these
523 interactions. The autocrine loop is indeed found to be the highest scoring growth factor interaction
524 also in human and mouse breast cancer.

525 The shared growth factors in the CAF autocrine loop include factors previously associated with
526 breast cancer and fibrosis. Co-inhibition of CXCL12 and TGFB1 together, was previously shown
527 to block the rewiring of fibroblasts to CAFs in breast cancer models ⁴⁰. The present data indicates
528 that each of these growth factors participates in an autocrine loop of a different CAF subtype:
529 CXCL12 in immune-regulatory CAFs, and TGFB1 in myofibroblastic CAFs. Thus, future studies
530 may explore precision modulation of CAF subpopulations by targeting specific growth factors.

531 The phase portrait approach also revealed organ-specific differences in the circuits in a non-
532 cancer context. Despite their similar fixed-points, the phase portraits for different organs are
533 generated by distinct inferred cell-cell interaction circuits, providing an organ-specific context to
534 the concept of cell-circuits. The organs differed in the existence of certain interactions in their
535 inferred circuits. Fat and lung fibroblasts lacked a paracrine growth interaction from macrophages,
536 and macrophages had an autocrine loop. In contrast, mammary fibroblasts showed paracrine
537 growth stimulation from macrophages, and macrophages lacked an autocrine loop. This
538 difference in inferred circuits leads to a basin of attraction seen most clearly in the lung phase
539 portrait, that is missing in the mammary phase portrait. This new basin of attraction, in which
540 macrophage levels decrease with time, can stabilize the ON-OFF state when macrophages are
541 lost in a small tissue region. Thus, lung and fat may be able to stabilize a state in which fibroblasts
542 support their own growth without macrophages, known as cold fibrosis ²³. Our transcriptomic
543 analysis indeed shows that lung and fat circuits are similar to each other and different from the
544 mammary circuit.

545 The present organ-specific circuits may be relevant also for understanding inflammation and
546 fibrosis. The ON state, in which high concentrations of BMDMs and fibroblasts co-exist, is known
547 as 'hot fibrosis' ²³. We find that this state is associated with high amounts of collagen deposition.
548 The state with only fibroblasts is called 'cold fibrosis', and we find that it has reduced collagen
549 deposition. In biological terms, hot fibrosis in the breast may be relevant to mastitis - a common
550 inflammatory response of the mammary gland caused by infection or injury ⁴⁸, whereas cold

551 fibrosis may occur in fibrocystic disease ⁴⁸. In the lung, a wide spectrum of interstitial diseases
552 with varying immune involvement (from hot to cold) culminate to self-perpetuating fibrosis ⁴⁹.
553 Fibrosis in the fat can occur in response to metabolic changes such as obesity ⁵⁰. The inferred
554 circuits suggest that all three organs can support hot fibrosis. These findings are supported by
555 transcriptomic data that shows ECM remodeling and inflammatory responses induced by co-
556 culture.

557 The circuit model allows one to test possible interventions *in-silico* that aim to manipulate the cell
558 populations in the cancer microenvironment. The simulated interventions are drugs that change
559 one of the circuit parameters, such as inhibitors of growth factor interactions - including antibodies
560 or receptor kinase inhibitors. One may seek interventions that collapse the populations of CAFs
561 and TAMs. Such an intervention is expected to also collapse the cancer cells due to the lack of
562 growth factors secreted by the microenvironment ⁵¹ and the lack of immune inhibition offered by
563 the microenvironment ^{12,52,53}.

564 One favorable combination of interventions emerges from the present circuit phase portrait
565 (Figure S6G). This combination entails inhibiting the autocrine loop of the CAFs and, at the same
566 time, inhibiting the growth factors for macrophages secreted by the cancer cells. Inhibition of the
567 CAF autocrine signaling loop would result in CAFs no longer supporting their own growth. The
568 ON and ON-OFF states are both lost when the inhibition is greater than a threshold (see
569 Methods). If this was all, the fibroblasts would collapse but the macrophages would survive,
570 supported by the cancer paracrine growth factors. Thus, a second intervention is needed in
571 parallel, to inhibit this paracrine support. Notably, one does not need to inhibit the interactions all
572 the way to zero, but rather only below a certain threshold ($p_{FF} < \frac{A_{rF}}{K_F}$, see Methods). The present
573 data indicates that each of these inhibitions may require targeting of multiple growth factors.

574 The co-culture circuit approach can be generalized to other organs and cell types. One could
575 explore, for example, different subpopulations of cancer-associated fibroblasts and macrophages,
576 potentially together with additional cell types such as T cells and cancer cells, in order to study
577 the circuits underlying the cancer microenvironment. The *in-vitro* system provides an accessible
578 platform to test the effect of specific manipulations on the circuit with the aim of sculpting the
579 cancer microenvironment towards therapeutic goals.

580 **Methods**

581 **Ethics statement**

582 All animal studies were conducted in accordance with the regulations formulated by the
583 Institutional Animal Care and Use Committee (IACUC; protocol #05420621-2). BALB/c
584 and C57BL/6 mice were purchased from Harlan Laboratories and maintained under specific-
585 pathogen-free conditions at the Weizmann Institute of Science (WIS) animal facility.

586

587 **Cancer cells**

588 4T1 murine triple negative breast cancer cells were a generous gift from the lab of Zvika Granot
589 (HUJI, Israel). These cells were transduced to express green fluorescent protein (GFP) using the
590 FUW-GFP vector. 4T1-GFP cells were cultured in Dulbecco's modified Eagle's medium (DMEM;
591 Biological Industries, 01-052-1A) with 10% fetal bovine serum (FBS; Invitrogen) and 5% P/S
592 (Biological Industries).

593

594 **4T1 condition medium**

595 4T1 cells were seeded at 1×10^6 cells/ml in 10 cm plates. 24 h later (when the cells have formed
596 a monolayer) the medium was replaced with fresh medium. 72h later, the medium was collected,
597 filtered through a 0.22 μ m strainer, and diluted with DMEM with 20% FBS, at a ratio of 1:1.

598

599 **Normal mammary fat pad and mesometrial fat fibroblasts isolation**

600 Normal mammary fat pad and mesometrial fat fibroblasts were isolated and dissociated from the
601 mammary fat pads or the fat tissue of two (BALB/c or C57BL/6, 8 weeks old) females per each
602 biological replicate. organs were minced and dissociated using a gentle MACS dissociator, in the
603 presence of an enzymatic digestion solution containing 1 mg/ml collagenase II (Merck Millipore,
604 234155), 1 mg/ml collagenase IV (Merck Millipore, C4-22) and 70 U/ml DNase (Invitrogen,
605 18047019), in DMEM. The samples were filtered through a 70 μ m cell strainer into cold PBS, and
606 cells were pelleted by centrifugation at 350g for 5 min at 4 °C, and resuspended in red blood cell
607 lysis buffer (BioLegend 420301), then washed with PBS and centrifuged at 350g for 5 min at 4 °C.
608 Mammary and fat fibroblasts were seeded on collagen I (Sigma-Aldrich, Cat. C3867) coated 10
609 cm or 6-well plates, respectively. The cells were expanded for 6 days in DMEM with 5% P/S and
610 10% of FBS and the media was replaced every 3 days.

611

612 **Primary Lung fibroblast isolation**

613 Lungs of BALB/c female (8 weeks old) were excised, dissociated, minced, and incubated with
614 enzymatic digestion solution containing 3 mg/ml collagenase A (Sigma Aldrich, 11088793001)
615 and 70 unit/ml DNase in RPMI 1640 (Biological industries, 01-100-1A) using a gentleMACS
616 dissociator, 30 min at 37°C. The samples were filtered through a 70-µm cell strainer into cold PBS
617 and cells were pelleted by centrifugation at 350g for 5 min at 4 °C and resuspended in red blood
618 cell lysis buffer, then washed with PBS and pelleted at 350g for 5 min at 4 °C. Lung fibroblasts
619 were seeded on 10cm plates coated with collagen I. The cells were expanded for 5 days in DMEM
620 with 5% P/S and 10% FBS, and medium was replaced after 3 days.

621

622 **Macrophage differentiation**

623 Bone marrow-derived macrophages from BALB/c (8 weeks old) female mice were differentiated
624 into macrophages by growth in DMEM with 10% FBS, 5% P/S and 20% L929 CM on a petri dish.
625 The medium was replenished at day 3, and the macrophages were reseeded for the experiment
626 on day 7.

627

628 **Macrophage-fibroblast co-culture**

629 The fibroblasts and the macrophages were isolated and expanded for 7 days, after which the
630 fibroblasts were trypsinized and resuspended in an ice-cold MACS buffer (PBS with 0.5% BSA).
631 The samples were pelleted by centrifugation at 350g for 5 min at 4 °C, incubated with anti-EpCAM
632 (Miltenyi, 130-105-958) and anti-CD45 (Miltenyi, 130-052-301) magnetic beads, transferred to LS
633 columns (Miltenyi, 130-042-401), and the fibroblast-enriched, CD45/EpCAM-depleted, flow-
634 through was collected. The macrophages were harvested with non-enzymatic cell dissociation
635 solution (Biological Industries, 03-071-1B) and washed with PBS without calcium and magnesium
636 (PBS (-/-)). The macrophages were stained with 2 µM CFSE and seeded together with the
637 fibroblasts in 96-well or 6-well plates precoated with collagen I. The co-cultures were grown in
638 DMEM with 10% FBS and 5% P/S, or with 4T1-conditioned medium (performed in parallel to
639 control media co-cultures). Every 3 days 50 µl/1ml of medium (for 96 well/6 well, respectively)
640 were replaced with fresh medium. Macrophages and fibroblasts were seeded at different
641 concentration ranges ($0-10^5$ in 96 well and $0-5 \times 10^6$ in 6 well), with the same combination of cell
642 concentrations seeded in parallel onto two different plates. Plates were analyzed by Flow
643 cytometry, one at day 3 and the other at day 7. Cell counts from 96-well plates were multiplied by
644 30 to scale for 6-well plates.

645

646 **Flow cytometry for cell quantification**

647 Fibroblasts and macrophages were harvested from tissue culture plates by incubation with a non-
648 enzymatic cell dissociation solution, washed, and transferred to round-bottom 96-well plates. The
649 cells were then counted by flow cytometry using CFSE and anti-CD11b-Pacific blue antibody
650 (Miltenyi, Cat.130-110-802) as positive markers for macrophages. Cells stained negatively for
651 these markers were counted as fibroblasts. Dead cells were excluded using DRAQ7 (Biolegend,
652 Cat. 424001). Flow cytometry was performed using CytoFlex-S (Beckman Coulter). FACS
653 analysis was performed using flowjo software v.10.7.1.

654

655 **EdU (5-ethynyl-20 -deoxyuridine) assay**

656 Mammary fibroblasts and macrophages were co-cultured in 96-well plates at a range of
657 concentrations ($0,1 \cdot 10^3$, $1 \cdot 10^4$ and $3 \cdot 10^4$), and an EdU incorporation assay was performed on
658 day 7. EdU (10 mM) was added to the cells for 2 hr, after which the cells were harvested, stained
659 with the live/dead exclusion marker Ghost-Dye-Violet450 (TONBO, Cat.13-0863), and with anti-
660 CD45-FITC (Miltenyi Biotec, Cat.130-110-658). EdU incorporation was detected using the Click-
661 iT Plus EdU Flow Cytometry Assay Kit according to the manufacturer's instructions
662 (ThermoFisher, Cat. C10634). Samples were then acquired using a CytoFlex-S (Beckman
663 Coulter), macrophages were gated based on positive staining for CD45, and fibroblasts were
664 called based on negative staining for this marker. Analysis was performed with FlowJo 10.7.1.

665

666 **Collagen deposition measurement *in-vitro***

667 Fibroblasts and macrophages were seeded in mono-culture or co-culture (0 , $1 \cdot 10^3$ and $1 \cdot 10^4$
668 cells), in 200 ul of DMEM, in collagen I pre-coated 96-well plates. Per experiment, at least two
669 technical replicates per condition were used. Cells were left for 7 days in culture to assure
670 confluence before performing collagen content measurement using a commercial Sirius Red
671 collagen staining kit (Chondrex, Cat.9046), and measured by Cytation 5-Imaging Reader (Biotek).

672

673 **Cell size determination**

674 Fibroblasts and macrophages were seeded in mono-culture at $3 \cdot 10^4$ cells in 8-well slide-
675 containing chambers (Ibidi, Cat.80826) that were pre-coated with collagen I. After 7 days, the
676 cells were fixed in 4% paraformaldehyde (PFA) for 10 min at RT, washed twice with PBS (-/-),
677 and stained with Dapi (to mark nuclei), and CellMask™ Deep Red plasma membrane stain
678 (ThermoFisher, Cat.C10046), according to the manufacturer's protocol. Images were taken with
679 a Nikon Eclipse Ci microscope $\times 10$ objective. Segmentation was done using Cellpose⁵⁴ with a

680 Flow threshold of 0.8 and a cell probability threshold of -1 on the DAPI and CellMask channel.
681 The cells that touched the borders were removed, and the cell sizes were quantified by QuPath
682 ⁵⁵ using the Cellpose segmentation.

683

684 **Bulk RNA-seq**

685 We performed RNA-sequencing of the co-cultures at the ON state. As control, we analyzed mono-
686 cultured fibroblasts and macrophages. Fibroblasts from different organs and BMDMs were
687 seeded at 3×10^5 into a pre-coated 6 well plate. The co-cultures and the mono-cultures were grown
688 in DMEM or 4T1-conditioned medium (as described above) and were collected after 7 days. The
689 macrophages mono-cultured were collected at day 0 since they cannot maintain themselves in
690 control medium, and at day 7 in cancer CM. 1×10^4 cells of fibroblasts and BMDMs were sorted
691 using the FACSMelody instrument (BD-biosciences). All live single cells (PI negative cells after
692 debris and doublet exclusion) were sorted. Cells staining positive for anti-CD11b-Pacific blue
693 (Miltenyi, 130-110-802) and anti-F4/80-APC Cy7 (Biolegend. cat.123117) were sorted as
694 macrophages, and cells staining negative for these markers were sorted as fibroblasts. The cells
695 were collected directly into lysis/binding buffer (Life Technologies), and mRNA was isolated using
696 Dynabeads oligo (dT) (Life Technologies). Library preparation for RNA-seq (MARS-seq) was
697 performed as previously described ⁵⁶. Libraries were sequenced on an Illumina NextSeq 500
698 machine and reads were aligned to the mouse reference genome (mm10) using STAR v.2.4.2a
699 ⁵⁷. Duplicate reads were filtered if they aligned to the same base and had identical UMIs. Read
700 count was performed with HTSeq-count ⁵⁸ in union mode, and counts were normalized using
701 DESeq2 ⁵⁹. Hierarchical clustering was carried out using Pearson correlation with complete
702 linkage, and on differentially expressed genes (DEGs), which were filtered with the following
703 parameters: basemean > 5; |log fold change| > 1 ; FDR < 0.1. Pathway analysis was performed
704 using Metascape ³³, significant pathways were determined if $P < 0.05$, and $FDR < 0.05$.

705

706 **Ligand-receptor analysis**

707 For the ligand-receptor analysis we used the ICELLNET R package ([https://github.com/soumelis-](https://github.com/soumelis-lab/ICELLNET)
708 [lab/ICELLNET](https://github.com/soumelis-lab/ICELLNET)) ³⁴. We used the Nichenet dataset ⁶⁰ and extracted the growth factor (ligand-
709 receptor) from this dataset based on growth factor activity Gene Ontology Term GO:0008083.
710 The scores were calculated based on the expression of genes, and as previously described ³⁴.
711 We performed this analysis on our normalized counts from our bulk RNA-seq of co-cultured
712 sequencing (Supplementary Tables 1-4), as described above. We also used published bulk RNA-

713 seq data of TAMs and CAFs from a 4T1 mouse model⁶¹. The normalized count genes were above
714 50 count in each population.

715

716 **Ligand-receptor analysis for scRNA-seq data processing and cluster annotation**

717 We used published scRNA-seq of breast cancer patients³⁹ and published scRNA-seq of 4T1
718 mouse breast cancer model⁴⁷. We filtered cells by cutoffs of gene and unique molecular identifier
719 count greater than 200 or lower than 10000, and a mitochondrial percentage less than 20%. We
720 used the Seurat v.3.0.0⁶² method in R v.4.2.0 for data normalization, dimensionality reduction,
721 and clustering, using default parameters. For mouse data we subgrouped myeloid, CAFs and
722 cancer clusters by known markers that were differentially expressed between the cultures. For
723 human data, the Normal and BRCA1 samples were removed from the analysis (BRCA1 samples
724 had few stromal cells, and added an expression effect that we couldn't overcome). Harmony
725 algorithm was used to correct for patient effect⁶³, and shared nearest neighbor (SNN) modularity
726 optimization-based clustering was then used. Cancer, Myeloid and CAF cell clusters were
727 selected based on classic cell markers, and selected for downstream analysis (275174 cells).
728 Matrix of normalized counts was used based on Harmony clusters. We used the same analysis
729 including only CAF cells, and revealed several CAF subtypes (91501 cells).

730

731 **Mathematical modeling of fibroblast-macrophage circuits**

732 The goal of the modeling was to infer the essential factors that influence the fibroblast-
733 macrophage circuit based on the cell count data, and to compare circuits that originate from
734 different contexts. These goals required a model with a minimal number of parameters to avoid
735 overfitting. We therefore used steady-state assumptions for growth factor concentrations, leaving
736 equations for the slower changes in cell numbers. We also incorporated detailed biochemical
737 reactions^{22,26} into a minimal number of effective interaction terms. These assumptions yielded a
738 simple model for the rate of change of cell population, X , which is a balance of proliferation and
739 removal at rates p_X and r_X , respectively:

740

$$741 \quad (1) \quad \frac{dX}{dt} = p_X X - r_X X$$

742

743 We describe the fibroblast-macrophage circuit by two such equations, one for each cell type ($X =$
744 F for fibroblasts and $X = M$ for macrophages). Fibroblasts and macrophages are removed at
745 constant rates, r_F and r_M , respectively. Autocrine and paracrine interactions influence the

746 proliferation rate, p_X , of each cell population through exchange of growth factors. Proliferation is
 747 limited at high cell concentrations by resources in the medium and by contact inhibition. To
 748 account for this, we used a carrying capacity term (K_X) that makes the proliferation rate decrease
 749 with growing cell population. This logistic term originates from population ecology, and was
 750 verified for fibroblasts by Zhou et al ²². Combining these effects yields the following equations:

751
 752 (2) $p_F = (p_{FF}f(F) + p_{MF}f(M)) \cdot (1 - \frac{f(F)}{K_F})$

753 (3) $p_M = (p_{FM}f(F) + p_{MM}f(M)) \cdot (1 - \frac{f(M)}{K_M})$

754
 755 p_{FF} and p_{MM} are the autocrine rates and p_{MF} and p_{FM} are the paracrine rates. These cellular
 756 interactions depend also on the population size, $f(X)$. Exploration of the data favored $f(X) =$
 757 $\log(X + 1)$, which represents a nonlinear relationship with diminishing relative effects of large cell
 758 populations. This nonlinear relationship provided better fits than a linear one, $f(X) = X$. Adding 1
 759 inside the log is common when working with counts, in order to avoid infinity at zero cells. The
 760 function f resembles the saturation effect in Michaelis-Menten (MM) interactions. We chose not
 761 to use MM expressions to keep the lowest number of parameters possible, because each MM
 762 term requires an additional 'halfway point' parameter.

763
 764 **Statistical inference**

765 Each cell-population equation has four parameters: the rates of autocrine (p_{XX}) and paracrine
 766 (p_{XY}) interactions, the rate of cellular death (r_X), and the carrying capacity (K_X). We sought to infer
 767 these parameters from the cell count measurements.

768 We divided equation (1) by the population size (X) to obtain the per-capita growth rate, which is
 769 also the logarithmic derivative: $\frac{1}{X} \frac{dX}{dt} = \frac{d \log X}{dt} = p_X - r_X$. In order to fit the data we approximated the
 770 derivative as the change in cell population in an experimental time interval (ΔT): $\frac{d \log X}{dt} \simeq \frac{\Delta \log X}{\Delta T} =$
 771 $\frac{\log(X(t+\Delta T)) - \log X(t)}{\Delta T}$. Reordering the equation gives:

772
 773 (4) $\log(X(t + \Delta T)) \simeq (p_X - r_X)\Delta T + \log X(t)$

774
 775 Taken together, each cell population number at day 7 (X_7) can be modeled by its number and the
 776 other cell population number at day 3, X_3 and Y_3 , where $\Delta T = 4$ days:

777

$$778 \quad (5) \log(F_7) \simeq 4 \left[(p_{FF} \log(F_3 + 1) + p_{MF} \log(M_3 + 1)) \cdot \left(1 - \frac{\log(F_3+1)}{K_F}\right) - r_F \right] + \log F_3$$

$$779 \quad (6) \log(M_7) \simeq 4 \left[(p_{FM} \log(F_3 + 1) + p_{MM} \log(M_3 + 1)) \cdot \left(1 - \frac{\log(M_3+1)}{K_M}\right) - r_M \right] + \log M_3$$

780

781 Parameters were constrained to be positive and estimated by the Trust Region Reflective (TRF)
782 method, a nonlinear least-squares approach⁶⁴. We used the python implementation of this
783 algorithm, *curve_fit*⁶⁵.

784 We tested which parameters are essential for the model fit using the Akaike Information Criterion
785 (AIC). Parameters not justified by this criterion were set to zero.

786 The experimental noise of the data led to uncertainty in parameter estimations. To estimate this,
787 we bootstrapped (resampling the data with returns) the measurements 5,000 times and inferred
788 the parameters for each draw by the TRF algorithm. This provided a distribution for each
789 parameter accounting for uncertainty and experimental noise.

790

791 The circuit equations with inferred parameters provided streamlines on a theoretical phase
792 portrait. We calculated the nullclines, defined as the set of points in the phase space where there
793 is no change in the population of one cell type ($dF/dt=0$ and $dM/dt=0$). The intersections between
794 these nullclines provided the fixed points of the system and their basins of attraction. The net
795 growth rate of each cell type from the model was displayed as heat maps, where growth rate
796 changes sign at the appropriate nullcline.

797

798 **Autocrine threshold for maintaining fibroblast population**

799 Under cancer CM, macrophages have no effect on fibroblasts growth. Therefore, the fibroblast
800 equation is:

$$801 \quad (1) \quad \frac{dF}{dt} = F \left(p_{FF} f(F) \cdot \left(1 - \frac{f(F)}{K_F}\right) - r_F \right)$$

802 Fibroblast population crushes when $\frac{dF}{dt} < 0$. Thus:

$$803 \quad (2) \quad -\frac{p_{FF}}{K_F} f^2(F) + p_{FF} f(F) - r_F < 0$$

804 To eliminate fibroblast's steady states and make them collapse in the whole space, inequality (2)
805 should hold for any F . This happens when $p_{FF} < \frac{4r_F}{K_F}$.

806

807

808 **Statistical analysis**

809 Statistical analysis and visualization were performed using R (Versions 3.6.0 and 4.2.0, R
810 Foundation for Statistical Computing Vienna, Austria) and Prism 9.1.1 (Graphpad, USA).
811 Statistical tests were performed as described in each Figure legend. In the Bulk RNA-seq, three
812 libraries (one sample of mono-cultured fat fibroblasts and two samples of mono-cultured
813 mammary fibroblast) were excluded due to technical problems with sequencing, as no reads were
814 detected.

815

816 **Data availability**

817 Bulk RNA-seq data that support the findings of this study were deposited in Gene Expression
818 Omnibus (GEO) and can be accessed via GSE217737. All other data supporting the findings of
819 this study are available from the corresponding author on reasonable request.

820

821 **Code availability**

822 For the ligand-receptor analysis we used the ICELLNET R package ([https://github.com/soumelis-](https://github.com/soumelis-lab/ICELLNET)
823 [lab/ICELLNET](https://github.com/soumelis-lab/ICELLNET)). We used the Seurat v.3.0.0 62 method in R v.4.2.0 to reanalyze published
824 scRNA-seq data. Phase portraits and parameter inference of the cell circuits were calculated
825 using Python and scipy package. Scripts and data needed to reconstruct the analysis and figures
826 will be uploaded to github before publication.

827

828 **References**

- 829 1. Mao, X. *et al.* Crosstalk between cancer-associated fibroblasts and immune cells in the
830 tumor microenvironment: new findings and future perspectives. *Mol Cancer* **20**, 131 (2021).
- 831 2. Binnewies, M. *et al.* Understanding the tumor immune microenvironment (TIME) for effective
832 therapy. *Nat Med* **24**, 541–550 (2018).
- 833 3. Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and
834 metastasis. *Nat Med* **19**, 1423–1437 (2013).
- 835 4. Gunaydin, G. CAFs Interacting With TAMs in Tumor Microenvironment to Enhance
836 Tumorigenesis and Immune Evasion. *Front Oncol* **11**, 668349 (2021).
- 837 5. Gieniec, K. A., Butler, L. M., Worthley, D. L. & Woods, S. L. Cancer-associated fibroblasts-
838 heroes or villains? *Br J Cancer* **121**, 293–302 (2019).
- 839 6. Franklin, R. A. Fibroblasts and macrophages: Collaborators in tissue homeostasis.
840 *Immunological Reviews* **302**, 86–103 (2021).
- 841 7. Meizlish, M. L., Franklin, R. A., Zhou, X. & Medzhitov, R. Tissue Homeostasis and
842 Inflammation. *Annu Rev Immunol* **39**, 557–581 (2021).
- 843 8. Bonnans, C., Chou, J. & Werb, Z. Remodelling the extracellular matrix in development and
844 disease. *Nat Rev Mol Cell Biol* **15**, 786–801 (2014).
- 845 9. Wang, Y. *et al.* Tissue-resident macrophages promote extracellular matrix homeostasis in
846 the mammary gland stroma of nulliparous mice. *eLife* **9**, e57438 (2020).
- 847 10. Shi, C. & Pamer, E. G. Monocyte recruitment during infection and inflammation. *Nat Rev*
848 *Immunol* **11**, 762–774 (2011).
- 849 11. Sahai, E. *et al.* A framework for advancing our understanding of cancer-associated
850 fibroblasts. *Nat Rev Cancer* **20**, 174–186 (2020).
- 851 12. Lavie, D., Ben-Shmuel, A., Erez, N. & Scherz-Shouval, R. Cancer-associated fibroblasts in
852 the single-cell era. *Nat Cancer* **3**, 793–807 (2022).
- 853 13. Kendall, R. T. & Feghali-Bostwick, C. A. Fibroblasts in fibrosis: novel roles and mediators.

- 854 *Front Pharmacol* **5**, 123 (2014).
- 855 14. Buechler, M. B., Fu, W. & Turley, S. J. Fibroblast-macrophage reciprocal interactions in
856 health, fibrosis, and cancer. *Immunity* **54**, 903–915 (2021).
- 857 15. Davidson, S. *et al.* Fibroblasts as immune regulators in infection, inflammation and cancer.
858 *Nat Rev Immunol* **21**, 704–717 (2021).
- 859 16. Buechler, M. B. *et al.* Cross-tissue organization of the fibroblast lineage. *Nature* **593**, 575–
860 579 (2021).
- 861 17. Costa, A. *et al.* Fibroblast Heterogeneity and Immunosuppressive Environment in Human
862 Breast Cancer. *Cancer Cell* **33**, 463-479.e10 (2018).
- 863 18. Friedman, G. *et al.* Cancer-associated fibroblast compositions change with breast cancer
864 progression linking the ratio of S100A4+ and PDPN+ CAFs to clinical outcome. *Nat Cancer*
865 **1**, 692–708 (2020).
- 866 19. Levi-Galibov, O. *et al.* Heat Shock Factor 1-dependent extracellular matrix remodeling
867 mediates the transition from chronic intestinal inflammation to colon cancer. *Nat Commun*
868 **11**, 6245 (2020).
- 869 20. Cassetta, L. *et al.* Human Tumor-Associated Macrophage and Monocyte Transcriptional
870 Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic
871 Targets. *Cancer Cell* **35**, 588-602.e10 (2019).
- 872 21. Mosser, D. M., Hamidzadeh, K. & Goncalves, R. Macrophages and the maintenance of
873 homeostasis. *Cell Mol Immunol* **18**, 579–587 (2021).
- 874 22. Zhou, X. *et al.* Circuit Design Features of a Stable Two-Cell System. *Cell* **172**, 744-757.e17
875 (2018).
- 876 23. Adler, M. *et al.* Principles of Cell Circuits for Tissue Repair and Fibrosis. *iScience* **23**,
877 100841 (2020).
- 878 24. Elyada, E. *et al.* Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma

- 879 Reveals Antigen-Presenting Cancer-Associated Fibroblasts. *Cancer Discov* **9**, 1102–1123
880 (2019).
- 881 25. Hwang, W. L. *et al.* Single-nucleus and spatial transcriptome profiling of pancreatic cancer
882 identifies multicellular dynamics associated with neoadjuvant treatment. *Nat Genet* **54**,
883 1178–1191 (2022).
- 884 26. Adler, M. *et al.* Endocytosis as a stabilizing mechanism for tissue homeostasis. *Proc Natl*
885 *Acad Sci U S A* **115**, E1926–E1935 (2018).
- 886 27. Mantovani, A., Marchesi, F., Malesci, A., Laghi, L. & Allavena, P. Tumour-associated
887 macrophages as treatment targets in oncology. *Nat Rev Clin Oncol* **14**, 399–416 (2017).
- 888 28. Guo, J. *et al.* Mouse 4T1 Breast Cancer Cell-Derived Exosomes Induce Proinflammatory
889 Cytokine Production in Macrophages via miR-183. *J Immunol* **205**, 2916–2925 (2020).
- 890 29. Zhou, X. *et al.* Microenvironmental sensing by fibroblasts controls macrophage population
891 size. *Proc. Natl. Acad. Sci. U.S.A.* **119**, e2205360119 (2022).
- 892 30. Hedrich, C. M. Shaping the spectrum - From autoinflammation to autoimmunity. *Clin*
893 *Immunol* **165**, 21–28 (2016).
- 894 31. Rigante, D., Emmi, G., Fastiggi, M., Silvestri, E. & Cantarini, L. Macrophage activation
895 syndrome in the course of monogenic autoinflammatory disorders. *Clin Rheumatol* **34**,
896 1333–1339 (2015).
- 897 32. Grom, A. A., Horne, A. & De Benedetti, F. Macrophage activation syndrome in the era of
898 biologic therapy. *Nat Rev Rheumatol* **12**, 259–268 (2016).
- 899 33. Zhou, Y. *et al.* Metascape provides a biologist-oriented resource for the analysis of systems-
900 level datasets. *Nat Commun* **10**, 1523 (2019).
- 901 34. Noël, F. *et al.* Dissection of intercellular communication using the transcriptome-based
902 framework ICELLNET. *Nat Commun* **12**, 1089 (2021).
- 903 35. Molnarfi, N., Benkhoucha, M., Funakoshi, H., Nakamura, T. & Lalive, P. H. Hepatocyte

- 904 growth factor: A regulator of inflammation and autoimmunity. *Autoimmun Rev* **14**, 293–303
905 (2015).
- 906 36. Scaldaferri, F. *et al.* VEGF-A links angiogenesis and inflammation in inflammatory bowel
907 disease pathogenesis. *Gastroenterology* **136**, 585-595.e5 (2009).
- 908 37. Wang, N. & Tian, B. Brain-derived neurotrophic factor in autoimmune inflammatory diseases
909 (Review). *Exp Ther Med* **22**, 1292 (2021).
- 910 38. Filippou, P. S., Karagiannis, G. S. & Constantinidou, A. Midkine (MDK) growth factor: a key
911 player in cancer progression and a promising therapeutic target. *Oncogene* **39**, 2040–2054
912 (2020).
- 913 39. Pal, B. *et al.* A single-cell RNA expression atlas of normal, preneoplastic and tumorigenic
914 states in the human breast. *EMBO J* **40**, e107333 (2021).
- 915 40. Scherz-Shouval, R. *et al.* The reprogramming of tumor stroma by HSF1 is a potent enabler
916 of malignancy. *Cell* **158**, 564–578 (2014).
- 917 41. Feig, C. *et al.* Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts
918 synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. *Proc Natl Acad Sci U S A*
919 **110**, 20212–20217 (2013).
- 920 42. Cheng, G. *et al.* Higher levels of TIMP-1 expression are associated with a poor prognosis in
921 triple-negative breast cancer. *Mol Cancer* **15**, 30 (2016).
- 922 43. Sa-Nguanraksa, D. & O-Charoenrat, P. The role of vascular endothelial growth factor a
923 polymorphisms in breast cancer. *Int J Mol Sci* **13**, 14845–14864 (2012).
- 924 44. Huang, T. *et al.* FGF7/FGFR2 signal promotes invasion and migration in human gastric
925 cancer through upregulation of thrombospondin-1. *Int J Oncol* **50**, 1501–1512 (2017).
- 926 45. Babazadeh, S. *et al.* Macrophage polarization by MSC-derived CXCL12 determines tumor
927 growth. *Cell Mol Biol Lett* **26**, 30 (2021).
- 928 46. Zhang, F. *et al.* TGF- β induces M2-like macrophage polarization via SNAIL-mediated

- 929 suppression of a pro-inflammatory phenotype. *Oncotarget* **7**, 52294–52306 (2016).
- 930 47. Sebastian, A. *et al.* Single-Cell Transcriptomic Analysis of Tumor-Derived Fibroblasts and
931 Normal Tissue-Resident Fibroblasts Reveals Fibroblast Heterogeneity in Breast Cancer.
932 *Cancers (Basel)* **12**, E1307 (2020).
- 933 48. Guray, M. & Sahin, A. A. Benign breast diseases: classification, diagnosis, and
934 management. *Oncologist* **11**, 435–449 (2006).
- 935 49. Wijsenbeek, M. & Cottin, V. Spectrum of Fibrotic Lung Diseases. *N Engl J Med* **383**, 958–
936 968 (2020).
- 937 50. DeBari, M. K. & Abbott, R. D. Adipose Tissue Fibrosis: Mechanisms, Models, and
938 Importance. *International Journal of Molecular Sciences* **21**, 6030 (2020).
- 939 51. Witsch, E., Sela, M. & Yarden, Y. Roles for growth factors in cancer progression. *Physiology*
940 (*Bethesda*) **25**, 85–101 (2010).
- 941 52. Bejarano, L., Jordão, M. J. C. & Joyce, J. A. Therapeutic Targeting of the Tumor
942 Microenvironment. *Cancer Discov* **11**, 933–959 (2021).
- 943 53. Mantovani, A., Allavena, P., Marchesi, F. & Garlanda, C. Macrophages as tools and targets
944 in cancer therapy. *Nat Rev Drug Discov* (2022) doi:10.1038/s41573-022-00520-5.
- 945 54. Stringer, C., Wang, T., Michaelos, M. & Pachitariu, M. Cellpose: a generalist algorithm for
946 cellular segmentation. *Nat Methods* **18**, 100–106 (2021).
- 947 55. Bankhead, P. *et al.* QuPath: Open source software for digital pathology image analysis. *Sci*
948 *Rep* **7**, 16878 (2017).
- 949 56. Massively Parallel Single-Cell RNA-Seq for Marker-Free Decomposition of Tissues into Cell
950 Types. [https://www.science.org/doi/10.1126/science.1247651?url_ver=Z39.88-](https://www.science.org/doi/10.1126/science.1247651?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%20pubmed)
951 [2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%20pubmed](https://www.science.org/doi/10.1126/science.1247651?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%20pubmed).
- 952 57. Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21 (2013).
- 953 58. Anders, S., Pyl, P. T. & Huber, W. HTSeq--a Python framework to work with high-throughput

- 954 sequencing data. *Bioinformatics* **31**, 166–169 (2015).
- 955 59. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for
956 RNA-seq data with DESeq2. *Genome Biol* **15**, 550 (2014).
- 957 60. NicheNet: modeling intercellular communication by linking ligands to target genes | Nature
958 Methods. <https://www.nature.com/articles/s41592-019-0667-5>.
- 959 61. Halperin, C. *et al.* Global DNA Methylation Analysis of Cancer-Associated Fibroblasts
960 Reveals Extensive Epigenetic Rewiring Linked with RUNX1 Upregulation in Breast Cancer
961 Stroma. *Cancer Res* OF1–OF14 (2022) doi:10.1158/0008-5472.CAN-22-0209.
- 962 62. Hao, Y. *et al.* Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573-3587.e29
963 (2021).
- 964 63. Korsunsky, I. *et al.* Fast, sensitive and accurate integration of single-cell data with Harmony.
965 *Nat Methods* **16**, 1289–1296 (2019).
- 966 64. Branch, M. A., Coleman, T. F. & Li, Y. A Subspace, Interior, and Conjugate Gradient
967 Method for Large-Scale Bound-Constrained Minimization Problems. *SIAM J. Sci. Comput.*
968 **21**, 1–23 (1999).
- 969 65. Virtanen, P. *et al.* SciPy 1.0: fundamental algorithms for scientific computing in Python. *Nat*
970 *Methods* **17**, 261–272 (2020).